Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France. Issue 2 (17th February 2018)

• Record Type: Journal Article
• Authors: Martin, Camille; Kizlik-Masson, Claire; Pèlegrin, André; Watier, Hervé; Viaud-Massuard, Marie-Claude; Joubert, Nicolas
• Is Part Of: MAbs. Volume 10:Issue 2(2018)
• Page Start: 210
• Page End: 221
• Publication Date: 2018-02-17
• Subjects: ADC -- bioconjugation -- immunoconjugate -- immunotherapy; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2017.1412130
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: The annual "Antibody Industrial Symposium", co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27–28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cytotoxic drug to a selective monoclonal antibody, which acts as a vector. Building on knowledge gained during the development of three approved ADCs, brentuximab vedotin (Adcetris®), ado trastuzumab emtansine (Kadcyla®) and inotuzumab ozogamicin (Besponsa®), and the many ADCs in development, this meeting addressed strategies and the latest innovations in the field from fundamental research to manufacturing.